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Abstract
Naturally acquired immunity against invasive pneumococcal disease (IPD) is thought to be
dependent on anti-capsular antibody. However nasopharyngeal colonisation by Streptococ-
cus pneumoniae also induces antibody to protein antigens that could be protective. We
have used human intravenous immunoglobulin preparation (IVIG), representing natural IgG
responses to S. pneumoniae, to identify the classes of antigens that are functionally relevant
for immunity to IPD. IgG in IVIG recognised capsular antigen and multiple S. pneumoniae
protein antigens, with highly conserved patterns between different geographical sources of
pooled human IgG. Incubation of S. pneumoniae in IVIG resulted in IgG binding to the bacte-
ria, formation of bacterial aggregates, and enhanced phagocytosis even for unencapsulated
S. pneumoniae strains, demonstrating the capsule was unlikely to be the dominant protec-
tive antigen. IgG binding to S. pneumoniae incubated in IVIG was reduced after partial
chemical or genetic removal of bacterial surface proteins, and increased against a Strepto-
coccus mitis strain expressing the S. pneumoniae protein PspC. In contrast, depletion of
type-specific capsular antibody from IVIG did not affect IgG binding, opsonophagocytosis,
or protection by passive vaccination against IPD in murine models. These results demon-
strate that naturally acquired protection against IPD largely depends on antibody to protein
antigens rather than the capsule.
Author Summary
Streptococcus pneumoniae is a major global killer. Invasive pneumococcal disease (IPD) is
the most severe form of infection. Surprisingly, the natural mechanisms of immunity to
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IPD in healthy individuals are unclear. The success of vaccines stimulating anti-capsular
antibodies have led to the belief that the same mechanism lies behind natural protection.
Using studies with pooled human immunoglobulin, we demonstrate that this is not the
case and instead IgG recognising the bacterial surface proteins appears to have the domi-
nant functional role. This finding supports efforts towards protein antigen-based vaccines,
and opens the possibility of stratifying potential risk for individuals of IPD.
Introduction
Streptococcus pneumoniae is a leading cause of infectious disease related death, responsible
annually for up to a million child deaths worldwide [1]. Pneumonia represents the greatest
burden of disease caused by S. pneumoniae [2], and despite current vaccination strategies the
burden of pneumococcal pneumonia remains high. Invasive pneumococcal disease (IPD) is
the most severe form of S. pneumoniae infection and mainly affects very young children and
older adults. This is attributed to an underdeveloped adaptive immune system in infants, and
to waning natural immunity combined with co-morbidities in the older adult. A clear under-
standing of the mechanisms of natural-acquired adaptive immunity to S. pneumoniae is essen-
tial to characterise why both the young and elderly are at high risk of disease and for the
development of effective preventative strategies. Vaccines based on the polysaccharide capsule
of S. pneumoniae are highly protective against the capsular serotypes included in the vaccine
preparation [3–5], and protection correlates with the level of anti-capsular antibody responses.
It has generally been assumed that the type-specific anti-capsular antibodies that can develop
in response to colonisation or episodes of infection are also the main mechanism of natural
adaptive immunity against IPD [6, 7]. However, there is little good evidence supporting the
concept that levels of anti-capsular antibodies predict risk of IPD in unvaccinated individuals.
As well as causing symptomatic disease, S. pneumoniae asymptomatically colonises the
nasopharynx, affecting at least fifty percent of infants and approximately ten percent of adults
[8]. Colonisation is an immunising event. In humans, it leads to antibody responses to capsular
polysaccharide [9], but also induces both antibody [10–14] and cellular immune responses to
protein antigens [15, 16]. Serum levels of antibody to multiple pneumococcal surface proteins
rise in the first few years of life [13], and have been show to fall in older age for a limited num-
ber of antigens [17]. Similar adaptive immune responses are observed in mouse models of
nasopharyngeal colonisation [11, 18–25]. In animal models, these anti-protein responses alone
can be protective, with T-cell mediated immunity preventing re-colonisation and non-invasive
pneumonia[15, 24, 25] and anti-protein antibody responses protecting against IPD [19, 20, 22,
24]. Recent human data suggests that Th17-cell mediated responses to protein antigens also
play an important role in protection against colonisation in humans [26] with implications for
vaccine design [27]. There are several converging lines of evidence from human studies which
support the concept that naturally-acquired anti-protein antibodies can also protect against S.
pneumoniae infections. Lower serum IgG levels to a range of pneumococcal proteins correlate
with susceptibility to acute otitis media [28, 29] and respiratory tract infections in children
[30]. Passive transfer of human serum from experimentally challenged human volunteers pro-
tected mice against invasive challenge with a different capsular serotype of pneumococcus
[20], providing proof of concept that ‘natural’ antibodies against bacterial proteins induced
through nasopharyngeal exposure can protect against IPD. Furthermore, the incidence of IPD
falls after infancy for all serotypes of S. pneumoniae, irrespective of how commonly the sero-
type is carried in the nasopharynx [31] suggesting that naturally-induced adaptive immune
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mechanisms are serotype-independent. If the protection against IPD that develops naturally
through colonisation requires anti-protein antibody responses rather than serotype-specific
anti-capsular antibody, this would represent an important readjustment in our understanding
of immunity to S. pneumoniae. It would have major implications for identifying subjects with
an increased risk of infection, understanding mechanisms of immunosenescence that increase
susceptibility to S. pneumoniae with age, and for guiding future vaccine design.
Passive transfer of pooled human immune globulin (IVIG) is an established treatment to
prevent infections in individuals with primary antibody deficiency [32, 33], in whom S. pneu-
moniae is a leading cause of disease [34]. Previous investigations in mice have indicated that
IVIG may protect against experimental IPD [35, 36]. Commercially-manufactured IVIG is
pooled immunoglobulin G (IgG) from >1000 different donors [37], and therefore represents
the pooled antibody responses acquired through natural exposure across a population. We
have used IVIG to determine the targets of natural acquired immunity to S. pneumoniae and
the relative functional importance of anti-capsular and anti-protein responses for prevention
of IPD.
Results
IVIG contains IgG that recognises both S. pneumoniae capsular and
proteins antigens
ELISAs using the whole S. pneumoniae cell as the antigenic target confirmed that IVIG con-
tained significant titres of IgG that recognised S. pneumoniae (Table 1). Polysaccharide-specific
ELISAs demonstrated that IVIG contained IgG that recognised common S. pneumoniae cap-
sular serotypes and cell wall polysaccharide (CWPS) (Table 1). To assess whether IVIG con-
tained IgG that bound S. pneumoniae proteins, immunoblots were performed against lysates
of several S. pneumoniae strains of differing capsular serotypes. Multiple protein antigens were
recognised by IVIG with a largely similar pattern of bands for all strains, suggesting the major
protein targets of IVIG are generally conserved between capsular serotypes of S. pneumoniae
Table 1. Antigen-specific IgG in IVIG. Whole cell ELISA titres to 3 different S. pneumoniae strains and
quantity of capsular-specific IgG for 10 S. pneumoniae capsular polysaccharides as measured by multiplex
MSD in IVIG (Intratect).
Whole cell ELISA
Strain (capsular serotype) Whole cell ELISA titre (log10 at OD 0.1)
TIGR4 (serotype 4) 4.72
D39 (serotype 2) 4.60
EF3030 (serotype 19F) 4.40
Anti-capsular antibody level
Serotype IgG(ng/ml)
1 22.3
4 10.4
5 23.4
6B 57.5
7F 33.1
9V 25.4
14 133
18C 36.4
19F 41.0
23F 40.2
doi:10.1371/journal.ppat.1006137.t001
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Fig 1. Antigen targets for IgG in IVIG. (A) Immunoblots of IVIG (1/1000) binding to whole cell lysates (10 μg
/ lane) of S. pneumoniae strains D39, TIGR4, 0100993, ST6B, ST14 and ST23F. (B) and (C) Competitive
inhibition in IVIG (1/10000) whole cell ELISAs of IgG binding to solid-phase S. pneumoniae TIGR4 using
increasing concentrations of (B) soluble lysates of TIGR4 with or without pre-treatment with trypsin, or (C)
soluble purified cell wall polysaccharide (CWPS), soluble serotype 4 capsule (CPS), or soluble S.
pneumoniae TIGR4 lysates. Data presented as means and SDs of four technical replicates and are
Natural Adaptive Immunity to Invasive Pneumococcal Disease
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(Fig 1A). Competitive inhibition was used to assess which antigens contributed significantly
towards the whole cell ELISA titres for the TIGR4 strain. Pre-incubation of IVIG with a soluble
bacterial lysate reduced whole cell ELISA IgG titres in a dose-dependent manner, which was
partially reversed by pre-treating the soluble lysate with the protease trypsin (Fig 1B). In con-
trast, neither purified capsular polysaccharide nor CWPS affected whole cell ELISA IgG titres
(Fig 1C). The whole cell ELISA assays were repeated for four different S. pneumoniae serotypes
with competitive inhibition by encapsulated and unencapsulated bacterial lysates (Fig 2A–
2D). The results demonstrated that for two of four strains lysates of encapsulated and unencap-
sulated bacteria equally reduced the IgG binding titre in the whole cell ELISAs. For the D39
(serotype 2) and serotype 3 strain whole cell ELISA titres were inhibited to a greater extent by
lysates of encapsulated bacteria compared to unencapsulated bacteria. Further whole cell ELI-
SAs for these two strains demonstrated that the unencapsulated mutants blocked IgG binding
to unencapsulated mutants (Fig 2E and 2F), indicating the reduced inhibition in the whole cell
ELISAs against the wild-type strain is likely to be due to the effects of anti-capsular antibody.
These data show that IVIG contains antibodies to both capsular, CWP and protein antigens,
but which class of antigens made the dominant contribution to IVIG recognition varied to an
extent between S. pneumoniae strains when assessed using whole cell ELISAs.
Identification of S. pneumoniae protein binding targets for human IgG
To identify protein targets for IgG in IVIG, lysates of S. pneumoniae mutants lacking specific
surface proteins were probed with IVIG. The results showed that IgG in IVIG recognised the
cell wall proteins PspA, PspC and PhtD and at least two lipoproteins (shown using the lipopro-
tein deficient strain Δlgt), including PiaA (Fig 3A). Immunoblotting of recombinant proteins
confirmed that IVIG contains IgG that recognises multiple (but not all) S. pneumoniae protein
antigens tested (Fig 3B). To assess whether protein targets for naturally acquired IgG to S.
pneumoniae were conserved between donors from different geographical regions we per-
formed immunoblots against S. pneumoniae lysates with a further commercially available
IVIG preparation (Vigam) obtained from the USA, and with sera pooled from 20 Malawian
subjects. The results showing an almost identical band pattern for each source of IgG (Fig 3C),
suggesting a high degree of consistency for the major protein antigen targets for IgG obtained
from different geographical regions. A Luminex assay of antibody binding to 19 different S.
pneumoniae surface proteins conjugated to xMAP beads was used to semi-quantify responses
from different sources of pooled human IgG to specific protein antigens. The Luminex assay
confirmed that IgG in IVIG recognised multiple protein antigens including PsaA, PpmA,
PhtD, PhtE, PspA, pneumolysin (Ply) and PspC (Fig 3D). Overall, the strength of IgG binding
to individual S. pneumoniae protein antigens between the different sources of antibody corre-
lated strongly, with PhtD and PspC as the dominant antigens in all three sources of pooled
human IgG (Fig 3D, and for correlation of Vigram versus Intratech R2 = 0.966).
S. pneumoniae target antigens vary partially between individuals and
with age
To assess whether there is significant variation between individuals in which S. pneumoniae
antigens are recognised by naturally acquired IgG, whole cell ELISAs to four S. pneumoniae
serotypes, immunoblots against S. pneumoniae lysates, the Luminex assay of protein antigen
representative of experiments repeated twice. P values calculated using 2-way ANOVAs and Bonferroni post-
test comparisons; error bars represent SD.
doi:10.1371/journal.ppat.1006137.g001
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responses, and capsular serotype antibody ELISAs were repeated using sera from six young
adult HIV negative Malawian individuals (mean age 29 years, range 21 to 36, 3 male, 3 female).
The results showed all the individuals investigated have significant anti-protein antibody
responses (Fig 4). However, there were variations between individuals in whole cell ELISA
titres to different S. pneumoniae strains (Fig 4A) and the levels of antibodies to some protein
antigens as shown by variations in band strengths in the immunoblot (Fig 4B) and in the
results for the Luminex bead assay (Fig 4C). For all the strains tested whole cell ELISA titres
from individuals correlated with the mean anti-protein antigen responses, whereas there was
no correlation to anti-capsule antibody levels except for the serotype 1 strain (S1 Fig). These
data support the hypothesis that anti-protein responses dominate IgG recognition of S. pneu-
moniae in human sera.
Fig 2. Effects of unencapsulated and encapsulated S. pneumoniae on IVIG whole cell ELISA titres for
four strains. Competitive inhibition of IVIG (1/10000) whole cell ELISAs of IgG binding to the homologous
solid-phase S. pneumoniae strain using increasing concentrations of encapsulated or unencapsulated
bacterial lysates for wild-type (A) TIGR4, (B) D39, (C) serotype 3, (D) serotype 23F strains, and for
unencapsulated mutant derivative of (E) serotype 3 and (F) D39 strains. Data presented as means and SDs of
three technical replicates.
doi:10.1371/journal.ppat.1006137.g002
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To investigate whether anti-protein antigen responses could be affected by age, an electro-
chemiluminescence-based multiplex assay based on MesoScale Discovery (MSD, Rockville,
MD, USA) technology [13] was used to measure responses to 27 protein antigens in sera
from 10 individuals aged over 62 years (mean 67.2 years) and 10 young adult individuals
(mean age 31.2 years). In general, mean anti-protein antigen responses were slightly lower
for the aged subjects (Fig 3D), with the most marked differences being for PspC (Fig 3E) and
PcpA (Fig 3F). The difference between older and younger sera reached statistical significance
for PspC.
Fig 3. Identification of protein antigens recognised by different sources of pooled IgG. (A) Immunoblots of IgG
(1/1000) binding to the wild-type S. pneumoniae strain D39 and isogenic mutant strains (10 μg) lacking specific surface
proteins using IVIG. Boxes highlight missing bands corresponding to the molecular weight for the protein(s) absent in
the mutant strains. (B) Immunoblots of IgG binding to selected recombinant S. pneumoniae proteins (0.5 μg / lane)
probed with IVIG (1/500). (C) Immunoblots of IgG binding to wild-type S. pneumoniae D39 strain (10 μg / lane) using
pooled sera from different geographical regions, commercial IVIG (1/3300) from Europe (Intratect) or USA (Vigam) and
from Malawi. (D) Linear regression of the rank order of strength of IgG binding to different protein antigens between
serum pooled from donors from Malawi and IVIG preparations obtained from the USA (Vigam) or Europe (Intratect).
Data points represent the rank order of each protein antigen for the mean MFI of two technical duplicates for IgG
binding measured using the Luminex assay. P and R2 values were obtained using F tests.
doi:10.1371/journal.ppat.1006137.g003
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Fig 4. Variation of IgG antigen targets between individuals and with age. (A-C) Results for six Malawian
subjects (labelled A to G). (A) whole cell ELISAs to 4 S. pneumoniae strains (serotype 4, 14, 9C and 1). (B)
Immunoblots of IgG binding to the wild-type S. pneumoniae strain D39 (10 μg / lane, red boxes highlight bands
that visibly vary in intensity between subjects). (C) MFI of IgG binding to selected protein antigens measured
using a Luminex assay. Data points represent mean (SEMs) of two technical duplicates for IgG binding. For
immunoblots and the Luminex assay, sera were diluted to 1/1000. (D) Levels of serum IgG binding to specific
protein antigens aged (mean age 67.2 years, black symbols) and young subjects (mean age 31.2 years, empty
symbols) measured by multiplex MSD (only results for antigens with stronger responses are shown as means
and SEM). (E-F) Levels of serum IgG binding for each individual aged (black symbols) and young (empty
symbols) adult subjects to the protein antigens PspC (E) and PcpA (F) measured by MSD. P values were
calculated using unpaired T tests, with bars representing means for the group.
doi:10.1371/journal.ppat.1006137.g004
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Human IgG binds to surface proteins on intact S. pneumoniae rather
than capsular polysaccharide
Functionally important IgG responses to S. pneumoniae were assessed using a flow cytometry
assay to measure total IgG binding to intact live bacteria from different S. pneumoniae strains.
Incubation in IVIG resulted in significant IgG binding to four different strains of S. pneumo-
niae. The level of IgG binding was either increased or unaffected when the assay was repeated
using otherwise isogenic unencapsulated mutant derivatives of each strain, indicating that
most of the IgG was binding to non-capsular antigens (Fig 5A and 5B). Conversely, pre-treat-
ment with Pronase to degrade surface protein antigens (Fig 5C), using D39 mutant strains
with reduced expression of dominant surface proteins (Δlgt, missing all lipoproteins, and
ΔpspA/pspC missing the corresponding choline binding proteins) (Fig 5D), or pre-incubation
of IVIG with an unencapsulated TIGR4 strain (Fig 5E), reduced the amount of IgG binding to
the TIGR4 strain suggesting proteins were the target antigens. To further demonstrate that
capsular polysaccharide was not the target for IgG binding, the assay was repeated using Strep-
tococcus mitis strains genetically manipulated to express the serotype 4 S. pneumoniae capsule
[37]. There was some binding of IgG in IVIG to the surface of the S. mitis strain indicating the
presence of antibodies to surface antigens. However, there was no increase in IgG binding to
the S. mitis strain expressing the S. pneumoniae serotype 4 capsule compared to wild-type S.
mitis (Fig 5F). Conversely, expression by S. mitis pspC, one of the dominant S. pneumoniae
protein antigens recognised by IgG in IVIG (Figs 3B, 3D, 4C and 4D), resulted in a large
increase in IgG binding (Fig 5G). These results indicate that protein antigens (including lipo-
proteins, PspA and PspC) rather than capsular polysaccharide are the major surface targets for
IgG binding to live S. pneumoniae.
Enrichment for heterologous anti-protein antigen responses maintains
protective efficacy of IgG from IVIG
To further assess whether immune recognition of live S. pneumoniae is dependent on IgG rec-
ognition of protein antigens, IgG from IVIG was selectively enriched for responses to S.
pneumoniae protein antigens using antibody affinity purification columns coated with unen-
capsulated S. pneumoniae lysates. The enriched IVIG (eIVIG) preparation made using either
the TIGR4 or D39 unencapsulated strains had a markedly higher whole cell ELISA titres to
both the TIGR4 and D39 encapsulated S. pneumoniae strains compared to untreated IVIG
(Fig 6A–6D). Despite the eIVIG preparation IgG concentration being only 30 μg/ml, approxi-
mately 1/150 the concentration in IVIG, incubation in eIVIG still resulted in IgG binding to S.
pneumoniae in the flow cytometry assay (Fig 6E–6F). These data confirm that IgG targeting S.
pneumoniae protein antigens can mediate IVIG immune recognition of S. pneumoniae.
IgG from IVIG promotes aggregation of S. pneumoniae independent of
capsular antigen
IgG binding to S. pneumoniae can cross-link bacteria to form bacterial aggregates that are
more susceptible to complement opsonisation [38]. Microscopy showed addition of IVIG to S.
pneumoniae TIGR4 resulted in the formation of bacterial aggregates (Fig 7A), the relative size
of which could be measured by flow cytometry using increases in forward scatter (Fig 7B).
Both encapsulated and unencapsulated TIGR4 S. pneumoniae formed bacterial aggregates in
IVIG, indicating these did not require recognition of capsular antigen (Fig 7A and 7B).
Furthermore addition of IVIG restricted the increase in OD580 over time for different S.
pneumoniae strains cultured in THY broth, and this effect was particularly noticeable for
Natural Adaptive Immunity to Invasive Pneumococcal Disease
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Fig 5. IgG binding to live S. pneumoniae after incubation with IVIG. (A) Effect of presence (wild-type strain,
+cps) or absence (unencapsulated strain, -cps) of the capsule on IgG binding to live S. pneumoniae TIGR4
incubated in either 1% IVIG, 10% IVIG or PBS (control). IgG binding was measured as MFI using anti-IgG-PE by
flow cytometry. (B) Effect of presence or absence of capsule on IgG binding to 3 other serotype strains (ST2,
strain D39; ST23F; ST3, strain 0100993) incubated in 10% IVIG. (C) Effect of pre-treatment of bacteria with
Pronase or PBS prior to incubation in 10% IVIG on IgG binding to TIGR4, and an example of the histogram for IgG
binding MFI (solid line, PBS then IVIG; dotted line PBS then Pronase then IVIG; shaded area, no IVIG). (D) Effect
of loss of expression of lipoproteins (Δlgt) or both the choline binding proteins PspA and PspC (ΔpspA/pspC) on
IgG binding to the D39 strain after incubation in 10% IVIG, with an example of the histogram for the MFI of IgG
binding (solid line, Δlgt; dotted line, ΔpspA/pspC; shaded area, D39). (E) Effect of depletion of specific surface
Natural Adaptive Immunity to Invasive Pneumococcal Disease
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unencapsulated strains (Fig 7C–7F). Vigorous pipetting raised the OD580 to similar levels for
both encapsulated and unencapsulated TIGR4 strains (Fig 7G), with no significant differences
in numbers of bacterial CFU between the strains (log10 CFU / ml for the TIGR4 strain 7.60 SD
0.14, for the TIGR4Δcps 7.85 SD 0.11 after 6 h incubation in THY plus 10% IVIG). These
results indicated that the reduction in the increase in OD580 over time in THY containing
IVIG was due to formation of bacterial aggregates. When IVIG was pre-treated with papain to
yield monovalent Fab fragments, the majority of the inhibitory effect of increase in OD580
effect was lost, confirming that bacterial aggregation was caused by cross-linking of bacterial
cells via the Fab portions of IVIG (Fig 7H). Overall, the aggregation data demonstrate that the
dominant target antigen for functionally important IgG binding to S. pneumoniae incubated
in IVIG was not the polysaccharide capsule.
IgG from IVIG promotes phagocytosis of S. pneumoniae TIGR4
independent of capsular antigen
In vitro assays were used to assess the effects of IVIG on interactions of encapsulated and
unencapsulated S. pneumoniae TIGR4 with phagocytes. Opsonisation with IVIG enhanced the
association of S. pneumoniae with a murine macrophage cell lines (Fig 8A) and with fresh puri-
fied human neutrophils (Fig 8B), and enhanced neutrophil killing of S. pneumoniae (Fig 8C).
For all three assays, IVIG had a proportionally greater effect on the unencapsulated strain than
the encapsulated strain. These data support the hypothesis that anti-capsular IgG is not impor-
tant in mediating the opsonophagocytic effects of natural human IgG present in IVIG.
IVIG provides macrophage-dependent protection against TIGR 4 IPD in
mice
Passive vaccination was used to investigate the protective efficacy of IVIG in different murine
models of S. pneumoniae TIGR4 infection. Mice were given a total of 12.8mg of IVIG (Intra-
tect, Germany, 40 g/L) in two separate i.p. injections 3 h and immediately before challenge
with S. pneumoniae. This IVIG dose was selected as it is equivalent to the doses used in replace-
ment therapy in primary immunodeficiency. In a test dose experiment, human IgG was readily
detectable in the sera of IVIG-treated mice three h following the second intraperitoneal injec-
tion at approximately 1.5 g/L, within the same order of magnitude of circulating IgG levels in
humans (7+ g/L) (Fig 9A). Human IgG was not detectable in mouse bronchoalveolar lavage
fluid (BALF) in uninfected mice. Following S. pneumoniae lung infection by i.n. inoculation of
5x106 CFU of TIGR4, human IgG concentrations increased in BALF over time (Fig 9B) and
correlated with BALF murine albumin levels, a marker of serum leak into alveolar spaces (Fig
9C). IVIG treatment had no effect on the inflammatory response to S. pneumoniae pneumonia,
both in terms of inflammatory cell numbers (S2 Fig) or levels of the pro-inflammatory cyto-
kine TNF-α in BALF post-infection (control group 2828 SEM 670 versus IVIG group 2665
SEM 506 pg/ml) in the lavage fluid following infection). IVIG treatment also had no effect on
bacterial CFU in lavage fluid 2.5 hours after low dose inoculation with TIGR4 (Fig 9D), a time
protein antibodies from 10% IVIG using absorption with unencapsulated TIGR4 prior to incubating wild type
TIGR4 bacteria in IVIG and measuring IgG binding using flow cytometry. (F) and (G) Effect of expressing potential
S. pneumoniae antigens in S. mitis on IgG binding to live bacteria after incubation in 10% IVIG. (F) IgG binding to
wild-type S. mitis (WT), S. mitis manipulated to lacking its own capsule (Δcps) or expressing S. pneumoniae
serotype 4 capsule (T4cps). (G) IgG binding to wild-type S. mitis (WT) or S. mitis expressing PspC. For all panels,
data are presented as means and SDs of three to four technical replicates and are representative of experiments
repeated at least twice. P values were calculated using unpaired 2-tailed Student t-tests.
doi:10.1371/journal.ppat.1006137.g005
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Fig 6. eIVIG immune recognition of S. pneumoniae. (A-D) Whole cell ELISAs of IgG binding to solid-phase S.
pneumoniae of increasing concentrations of eIVIG made using TIGR4 (A and B) or D39 (C and D) or IVIG.
Binding was assessed to the solid phase strain that was homologous (A and D) or heterologous (B and C) to the
enrichment strain. (E-F) Bacterial surface IgG binding measured by flow cytometry to S. pneumoniae TIGR4 (E)
or D39 (F) incubated in either PBS (shaded area) or TIGR4 eIVIG at 30 μg/ml (solid line). P values were
calculated using linear regression for panels A, B, C, and D, and unpaired 2-tailed Student t-tests for panels E and
F.
doi:10.1371/journal.ppat.1006137.g006
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point and inoculum dose when alveolar macrophages are the main effector cell [38]. However,
at 24 h following challenge, infected mice that had been pre-treated with IVIG were strongly
protected against the development of bacteraemia (present in 100% of controls but only 17%
of IVIG treated mice) and partially protected against lung infection, with 2 log10 fewer S. pneu-
moniae CFU in lung tissue compared to controls (Fig 9E). Pre-treatment with IVIG also pro-
tected mice against developing bacteraemia 4 h following direct i.v. bacterial challenge (Fig
9F). Protection against bacteraemia required macrophages, since their depletion by pre-
Fig 7. IVIG causes aggregation of both encapsulated and unencapsulated S. pneumoniae. (A) Light
microscopy of bacteria (at 100 X with rapid Romanovsky stain) after 8 hr culture of wild-type (TIGR4) and
unencapsulated (TIGR4Δcps) bacteria with or without 10% IVIG. (B) Effect of relative concentration of IVIG
on size of bacterial aggregate particles after 30 minute incubation of wild-type (open bars) or unencapsulated
(filled bars) TIGR4 measured as forward scatter in flow cytometry. P values were calculated using one-way
ANOVA. (C) to (F) Changes in optical density at 580nm (OD580) during culture of wild-type (triangles) and
unencapsulated (circles) S. pneumoniae (C) TIGR4, (D) ST2 (D39), (E) ST3 (0100993), (F) or ST23F strain in
THY broth supplemented with either 10% IVIG (filled symbols) or PBS (empty symbols). (G) Effect of vigorous
pipetting (filled symbols) or no pipetting (empty symbols) immediately prior to measurement of OD580 during
culture of wild-type (triangles) and unencapsulated (circles) TIGR4 in 10% IVIG. (H) Effect of addition of either
1% IVIG (filled circles) or 10% (upside triangles), 5% (diamonds) or 2% (crosses) papain-treated IVIG, or PBS
(empty circles) on OD580 during culture of unencapsulated TIGR4. For panels B to H, data are presented as
means and error bars represent SDs of three to four technical replicates and are representative of
experiments repeated at least twice. *, P<0.001 compared to PBS or non-pipetted controls by two way
ANOVA.
doi:10.1371/journal.ppat.1006137.g007
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treatment with liposomal clodronate (Fig 9G) reduced IVIG-dependent S. pneumoniae clear-
ance from the blood (Fig 9H). The partial protection provided by IVIG within the lungs was
lost when mice were depleted of neutrophils before infection by treatment with anti-Ly6G
antibody (Fig 9I). Mice depleted of neutrophils failed to develop bacteraemia even without pas-
sive vaccination with IVIG. These data confirm that passive vaccination with IVIG strongly
protects mice against IPD, and that protection was dependent on phagocytes.
IVIG-mediated protection is not dependent on presence of anti-capsular
IgG
To directly demonstrate that the protection afforded by IVIG is not mediated via anti-capsular
antibody, IVIG was pre-treated to deplete anti-capsular antibody prior to testing its protective
effects against IPD in vivo. Selective depletion of capsular serotype 4 specific antibody
Fig 8. IVIG improves macrophage and neutrophil opsonophagocytosis of both encapsulated an
unencapsulated S. pneumoniae TIGR4. (A) MFI and example of a histogram of the fluorescence of RAW
macrophages incubated with fluorescent (FAM-SE labelled) encapsulated (clear columns) and
unencapsulated (black columns) S. pneumoniae TIGR4 strains with and without addition of 10% IVIG. P
values were calculated using unpaired 2-tailed Student t-test. (B) MFI of fluorescence intensity of human
neutrophils following incubation with FAM-SE labelled S. pneumoniae TIGR4 encapsulated (clear columns)
and unencapsulated (filled columns) strains pre-opsonised with increasing concentrations of IVIG. P values
were calculated using one-way ANOVAs. (C) Relative survival of S. pneumoniae TIGR4 encapsulated (+cps)
and unencapsulated (-cps) strains following incubation with human neutrophils in the presence of 10% IVIG.
Percentage survival calculated relative to survival of identical strain incubated without IVIG, with the surviving
CFU / ml shown for control versus 10% IVIG above each column. For all panels, data are presented as means
and SDs of three to four technical replicates and are representative of experiments repeated at least twice. P
values were calculated using unpaired 2-tailed Student t-test (A and C) or one way ANOVAs (B).
doi:10.1371/journal.ppat.1006137.g008
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Fig 9. Passive vaccination with IVIG protects against IPD in murine models of S. pneumoniae infection. Mice
were passively vaccinated by i.p. administration of 12.8 mg of IVIG (Intratect) or PBS 3 hours before challenge with
S. pneumoniae. (A) and (B) Concentration of human IgG measured by ELISA after (A) in mouse sera 3 h post-IVIG
(n = 4), and (B) in mouse BALF recovered from mice 3 h post-IVIG and immediately before and at 2.5 and 24 h after i.
n. challenge with 107 CFU of TIGR4 strain S. pneumoniae (n = 4 to 6). (C) Correlation between concentration of
murine albumin (mg/ml) and human IgG (μg/ml) in BALF 24 hr following invasive i.n. challenge in IVIG-treated mice
(n = 6); P and r2 values were calculated using the F test. (D) Bacterial CFU (log10) recovered from BALF 2.5 hr
following IN challenge with 5x105 CFU of TIGR4 of IVIG-treated or PBS-treated control mice (n = 6 or 7). (E) Bacterial
CFU (log10) recovered from BALF, lung tissue or blood 24 hr following IN challenge with 107 CFU of TIGR4 of IVIG-
treated or PBS-treated control mice (n = 6). (F) Bacterial CFU (log10) recovered from blood 4 hr following i.v.
challenge with 5x105 CFU of TIGR4 of IVIG-treated or PBS-treated mice (n = 5). (G) Effect of administration of i.v.
100 μl liposomal clodronate (5mg/ml) to mice on the numbers of F4/80+ve splenocytes measured by flow cytometry
(n = 6), with data presented as means, error bars represent SDs, and P values were calculated using unpaired 2-tail
Student t-test. (H) Effect of clodronate or PBS administration on bacterial CFU (log10) recovered from the blood of
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depletion was achieved by incubating IVIG with the S. mitis strain expressing the S. pneumo-
niae serotype 4 capsule. This process had no effect on the pattern and level of IgG binding to
protein antigens in immunoblot and in ELISA for at least two specific proteins (Fig 10A).
Whilst the depletion process almost completely removed serotype 4 anti-capsular IgG from
IVIG-treated mice 4 hr following i.v. challenge with 5x105 CFU of TIGR4 (n = 5). (I) Bacterial CFU (log10) recovered
from the lungs of neutrophil depleted mice (by prior treatment with the antiLy6 antibody 1A8) given either IVIG or PBS
24 hr and then inoculated i.n. with 5x106 CFU of TIGR4 (n = 11 or 12). For (A, B, D, E, F, H, I), symbols represent
data from individual mice, bars represent group means, and P values were calculated using unpaired 2-tail Student t-
test. Dashed lines represent the limit of detection.
doi:10.1371/journal.ppat.1006137.g009
Fig 10. Absorption of anti-capsular antibody does not prevent IVIG protection against murine models of
IPD. (A) Mean (SD) anti-PsaA titres measured by ELISA in IVIG following depletion of type 4 specific IgG by pre-
absorption with type 4 capsule expressing S. mitis. (B) Mean (SD) anti-capsular serotype 4 titre IgG titre
measured by ELISA in type 4 specific IgG-depleted IVIG. (B) Mean (SD) MFI of anti-human IgG binding to wild-
type (clear columns) and unencapsulated (black columns) S. pneumoniae TIGR4 following incubation in 1% or
10% in type 4 specific IgG-depleted IVIG. (C) Bacterial surface IgG binding measured by flow cytometry to S.
pneumoniae TIGR4 incubated in PBS (grey column), 1% or 10% mock absorbed IVIG with (filled columns) or
type 4 specific IgG-depleted IVIG (open columns). For panels (A) to (C) data are presented as means and SDs of
three to four technical replicates and representative of experiments repeated at least twice. (D) Log10 CFU
recovered from BALF, lungs, and blood 24 h after i.n. challenge with 1x107 CFU S. pneumoniae TIGR4 for mice
pre-treated with 12.8 mg of type 4 specific IgG-depleted IVIG or PBS. (E) Log10 CFU recovered from blood 4 h
after i.v. challenge with 5x105 CFU S. pneumoniae TIGR4 for mice pre-treated with PBS (open circles), or 12.8
mg of mock absorbed IVIG (black circles) or type 4 specific IgG-depleted IVIG (grey circles). Data for panels (D)
and (E) were obtained using IVIG depleted of capsular antibody on separate occasions; symbols represent data
from individual mice, bars represent group means, and P values were calculated using unpaired 2-tail Student t-
test (D) or one way ANOVA (E). Dashed lines represent the limit of detection.
doi:10.1371/journal.ppat.1006137.g010
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the IVIG (Fig 10B), it had no effect on total IgG binding to the surface of S. pneumoniae when
assessed by flow cytometry (Fig 10C). Passive transfer of IVIG depleted of type 4 serotype spe-
cific antibody to mice still protected against bacteraemia developing after i.n. inoculation of
TIGR4 S. pneumoniae (Fig 10D), and after i.v. inoculation of TIGR4 restricted blood CFU to
similar levels seen in mice given untreated IVIG (Fig 10E). These data confirm that IVIG
does not require IgG to capsular polysaccharide to protect against invasive infection due to S.
pneumoniae.
Discussion
The bimodal distribution of S. pneumoniae infections in the very young and elderly suggests
there is a significant degree of naturally-acquired immunity that evolves in early life and then
wanes in later life. This naturally-acquired immunity is probably acquired through multiple
episodes of nasopharyngeal colonisation with S. pneumoniae that repeatedly affect all humans
rather than solely after disease episodes [16, 18–20, 24, 31]. Human epidemiological and exper-
imental evidence from mouse models of infection suggest naturally-acquired immunity has a
serotype-independent component [20, 28, 29, 31], yet the assumption remains that antibody
to capsular antigen is the dominant mechanism of protection against IPD [6, 7]. As a conse-
quence, clinical assessment of susceptibility to IPD is dependent on measuring anti-capsular
IgG levels.
IVIG is a source of pooled IgG that contains naturally-acquired antibody to S. pneumoniae.
We have used in vitro and in vivo experiments to compare the relative functional importance
of the anti-capsular and anti-protein antigen IgG in mediating protection against S. pneumo-
niae. Overall, the data show greater importance for anti-protein rather than anti-capsular IgG,
summarised as follows: (1) For both surface binding of IgG measured by flow cytometry and
in vitro aggregation capsular antigen was not the main target for the four serotypes investi-
gated. Data from the whole cell ELISAs were more mixed, with evidence of some contribution
of anti-capsular IgG for two of the four strains assessed. However, IgG surface binding to live
bacteria has been show to be a better surrogate for protection than ELISA titre [18]. (2) Enzy-
matic degradation of surface proteins, absorbtion of anti-protein antibody by incubation with
unencapsulated TIGR4 strain, or reduced expression of some classes of surface proteins due
to mutation all reduced total IgG binding to S. pneumoniae. (3) Expression by S. mitis of an
immunodominant protein antigen but not the serotype 4 capsule increased IgG recognition
when incubated in IVIG. (4) A low concentration of an IVIG derivative enriched for anti-pro-
tein responses to S. pneumoniae recognised heterologous S. pneumoniae strains in whole cell
ELISA and flow cytometry IgG binding assays. (5) Loss of the capsule did not impair the pro-
tective effects of IgG in functional assays of neutrophil and macrophage phagocytosis of the
TIGR4 S. pneumoniae strain. (6) Specific depletion of serotype 4 anti-capsular antibodies from
IVIG had no effect on IgG binding to intact bacteria and did not abrogate the ability of IVIG
to protect against IPD when tested in mouse models of infection. These data form the first evi-
dence to our knowledge demonstrating the redundancy of naturally-acquired human IgG
against capsular antigens in protection against IPD, with protection afforded by anti-protein
antibody instead. By necessity, the four strains investigated represent only a proportion of the
97 S. pneumoniae capsular serotypes currently known [39], and we have only been able to
deplete anti-capsular antibody for the serotype 4 strain as this is the only available S. pneumo-
niae capsular serotype expressed in S. mitis. Hence, although the in vitro aggregation and IgG
binding data suggest capsule antigen is not functionally relevant for the four serotypes investi-
gated, it remains possible that for selected serotypes anti-capsular antibody has a greater role
in mediating protection against IPD than we have identified here. In addition, as we have not
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been able to make a sufficient quantity of an IVIG derivative effectively depleted of anti-pro-
tein antigen responses, we have not been able to explicitly demonstrate in the mouse model of
infection that protection is dependent on anti-protein responses rather than to other potential
non-capsule non-protein antigens. Our data also do not preclude an important role for natu-
rally-acquired antibody to capsular antigens at other body sites, for example for prevention of
nasopharyngeal colonisation [40]. Despite these caveats, the different strands of data we have
presented here provide strong support for the hypothesis that the protection in humans against
IPD mediated by naturally acquired IgG is not dependent on capsular antibodies. Instead pro-
tection seems to require recognition of bacterial surface proteins.
Protection against S. pneumoniae infection depends on phagocytes, with different cell types
having dominant roles at different anatomical sites and at different time points. Alveolar
macrophages are important for bacterial clearance during early lung function [38], whereas
recruited neutrophils are important for controlling bacterial numbers in the lung at later time
points [41]. In mice at least, protection against S. pneumoniae bacteraemia and therefore IPD
is highly dependent on splenic and reticuloendothelial macrophages [42]. In the mouse model
of S. pneumoniae lung infection, passive vaccination with IVIG did not reduce BALF CFU,
even at early time points after low dose infection. These results suggest that alveolar macro-
phages did not mediate the protective effect, although this has not been formally confirmed by
infections in mice depleted of alveolar macrophages. Depletion of neutrophils prevented the
protective efficacy of IVIG within the lung, whereas systemic depletion of macrophages pre-
vented its protective efficacy in the blood. Unexpectedly, depletion of neutrophils prevented
septicaemia in the mouse model of pneumonia, preventing this model from being used to
assess whether there is a role for neutrophils in IVIG-mediated protection against bacteraemia.
Investigating this would require using neutrophil depletion in the systemic infection model,
which we have not assessed. IVIG therapy has been used for immunomodulation, but in our
model did not affect cellular recruitment to lavage fluid or TNFα responses. These results
suggest that IVIG had no major effects on the inflammatory response to S. pneumoniae,
although they do not exclude potentially beneficial effects on other aspects of the inflammatory
response.
We have demonstrated that IgG in IVIG recognises a large number of S. pneumoniae pro-
tein antigens, several of which were identified using immunoblots and a Luminex assay and
these include current protein vaccine candidate antigens [43]. There was a striking similarity
between which protein targets were quantitatively dominant in binding IgG in IVIG from dif-
ferent geographical sources, with PspA, PhtD, PsaA and PpmA having the strongest antibody
recognition in all IgG sources investigated. These similarities suggest that the immunodomi-
nance of certain protein antigens is largely independent of human genetic variation. Our pro-
tein target identification was biased towards existing well-described antigens, and further non-
biased assessment is needed to identify all the antigens recognised by naturally acquired anti-
body. Several of the immunodominant surface proteins such as PspC and PspA are antigeni-
cally variable, and as only a single variant was represented on the Luminex assay it is unclear
whether antibody recognition of these antigens is specific to certain alleles. Expression of PspC
did increase IgG binding to live S. mitis, and for the D39 strain deletion of surface lipoproteins
or both PspA and PspC both reduced IgG binding. These data suggest that PspC, PspA and
lipoproteins may contribute towards IgG recognition of S. pneumoniae, but further investiga-
tion is necessary to identify which protein antigens are required for the protective IgG
responses. This will be technically challenging as it is highly likely there is functional redun-
dancy for IgG binding to S. pneumoniae surface proteins, and using mutants lacking specific
protein antigens to identify functionally important targets for IgG in mouse infection models
will be confounded by the importance for virulence of many of the potential protein antigens
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(e.g. PspA, PspC, Ply, PhtD). We also demonstrated IgG binding to S. mitis itself, which may
be due to cross-recognition of S. mitis and S. pneumoniae surface antigens, or specific
responses to S. mitis induced by natural oropharyngeal colonisation.
These data demonstrating that antibodies to S. pneumoniae capsular polysaccharide are not
the major target of protective naturally acquired IgG have several important clinical implica-
tions. Firstly, measuring levels of anti-capsular antibody may not identify those patients at risk
of IPD. Instead, measurement of antibodies to a range of protein targets or to whole S. pneu-
moniae by flow cytometry may be more relevant. Secondly, it may explain why individuals
with specific-deficiencies in anti-polysaccharide antibody production, who are at increased
risk of sino-pulmonary infection do not have the same high risk for invasive IPD as subjects
with complete agammaglobulinaemia [44, 45]. Thirdly, the exponential rise in the incidence of
S. pneumoniae infection with increasing age is thought to be related to immunosenescence.
Antigen responses to a small number of protein antigens have been shown to be lower in the
elderly [17], and we have also shown reduced responses to PspC in a small number of older
subjects. These data suggest that one reason for the increased incidence of S. pneumoniae with
age could be waning anti-protein antibody levels. Further investigation of the effects of age on
anti-protein antigen responses and the functional consequences of any changes is needed to
establish whether this hypothesis is correct. Fourthly, if there is reduction in S. pneumoniae
colonisation in infants as a result of future vaccines with greater serotype coverage, this could
potentially reduce anti-protein mediated natural immunity and perhaps lead to a paradoxical
increase in adult disease, as has been postulated for the effects of Bordetella pertussis vaccina-
tion [46]. Finally, by identifying the mechanisms of naturally acquired immunity to S. pneumo-
niae, we can design vaccination strategies to improve these. For example, a multivalent protein
vaccine using the dominant protein antigens should provide effective protection against IPD.
To conclude, we present multiple lines of supporting evidence that the protective benefits
of human naturally acquired IgG against IPD is not, as previously thought, largely dependent
on antibody to capsular polysaccharide antigen. Instead, natural human IgG-mediated protec-
tion against IPD seems to be dependent on IgG against protein antigens that are highly
conserved between different geographical sources of IgG. These findings have important
implications for identifying patients at risk of IPD, understanding relevant mechanisms of
immunosenescence, and for novel vaccine development.
Materials & Methods
Bacterial strains, culture and manipulation
Wild-type S. pneumoniae serotype 4 strain TIGR4 and its unencapsulated mutant were kind
gifts of J. Weiser (Univ. Pennsylvania). D39 and its unencapsulated mutant D39-DΔ were kind
gifts of J. Paton (Univ. Adelaide). The ΔpspC, ΔpspA, ΔppmA, Δlgt, ΔphtD, ΔpiaA, and Δply
mutant strains have been previously described [47–51]. Serotype 19F strain EF3030 was a kind
gift of D. Briles (Univ. Alabama), and the serotype 6B stain ST6B, serotype 14F strain ST14,
and serotype 23F strains were kind gifts from B. Spratt (Imperial College). The unencapsulated
mutant strains of 0100993 and ST23F were made by replacing the cps locus (Sp_0346 to
Sp_0360) with the Janus cassette [52]. The S. mitis strain expressing the S. pneumoniae TIGR4
serotype 4 capsule has been previously reported [53]. To construct the S. mitis pspC+ mutant
strain, the TIGR4 pspC gene was amplified by PCR and integrated between S. mitis flanking
DNA using PCR ligation before transformation into the S. mitis strain, similar to the mutagen-
esis strategy as described [22]. Bacteria were cultured overnight at 37˚C in 5% CO2 on Colum-
bia agar (Oxoid) supplemented with 5% horse blood (TCS Biosciences). Working stocks were
made by transferring one colony of S. pneumoniae to Todd-Hewitt broth supplemented with
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0.5% yeast extract (THY), grown to an OD of 0.4 (approximately 108 CFU/ml) and stored at
-80˚C in 10% glycerol as single use aliquots. CFU were confirmed by colony counting of log10
serial dilutions of bacteria cultured overnight on 5% Columbia blood agar. To partially digest
surface proteins, bacteria were suspended in 500μl PBS with or without 100μg Pronase
(Roche), incubated for 20min at 37˚C shaking at 150rpm, followed by addition of 20μl of 25X
Complete Mini-Protease Inhibitor (Roche). Bacteria were then washed twice in PBS and re-
suspended in PBS+10% glycerol. Bacterial lysates were prepared as described previously [48].
When required, 20μl of lysate (1500 μg/ml) was treated with 10μl trypsin (2.5mg/ml, Gibco,
Invitrogen) or PBS (control lysates) and incubated overnight, before the addition of 10μl 25X
Complete Protease Inhibitor (Roche).
Serum sources and IVIG
Intratect was a kind gift of Biotest Pharma GmbH, Dreieich, Germany. Vigam (Bioproducts
Laboratories Ltd, Elstree, UK) was obtained commercially. Both contain 5% pooled human
intravenous immunoglobulin. Dilutions of IVIG described for experimental data refer to dilu-
tions of the 5% product rather than the resulting IgG concentration. Individual sera were col-
lected from HIV-negative healthy adults in Malawi (age range 19 to 49 years, mean 29 years,
16 male and 4 female) who had not been immunised against S. pneumoniae. Serum from
elderly subjects (age range 62 to 78 years, 6 males, 4 females) and young adult controls subjects
(age range 24 to 33 years, 4 males, 6 females) was a kind gift from Dr Elizabeth Sapey, Univer-
sity of Birmingham. Specific antibody was depleted from IVIG by bacterial surface absorption
with either unencapsulated TIGR4 or S. mitis expressing the serotype 4 capsule [53]. Bacteria
were grown to OD580 0.4, washed and re-suspended to OD 1.0 using PBS, and 4mls were pel-
leted by centrifugation before re-suspension in 1.8mls of IVIG (Intratect). The suspension was
incubated for 1hr at 37˚C, shaking at 100rpm. The antigen-depleted IVIG was recovered by
centrifugation and the process repeated. Mock absorbed IVIG was prepared by following the
same process but without addition of bacteria. IVIG was pre-treated with papain to yield
monovalent Fab fragments using the Pierce Fab Preparation Kit according to the manufactur-
er’s instructions and confirmed by immunoblot. Enriched (e)IVIG was prepared by affinity
chromatography as previously described [54]. For the affinity resin, unencapsulated TIGR4 or
D39 cultures were grown for 16h, pelleted and resuspended in 1 volume of coupling buffer
(0.1 M Sodium bicarbonate, 0.5 M Sodium chloride; pH 8.3). Cells were pressure lysed at 200
MPa using a pressure cell homogeniser (Stansted) and the resulting lysates were 0.2 μm filtered
and dialysed against 5L of coupling buffer for 4 h at RT. Lysates were concentrated using
Vivaspin 20 centrifugal concentrators with a molecular weight cut of 10 kDa (GE healthcare)
and coupled to cyanogen bromide activated agarose (Sigma-Aldrich) at a concentration of
approximately 1 mg/ml according to the manufacturer’s instructions.
Serology and antibody assays
Whole cell, or specific antigen (individual proteins, capsular polysaccharide or cell wall poly-
saccharide) ELISAs were performed as previously [18, 55–57]. Recombinant PhtD was a kind
gift of C. Durmort [58] and PsaA was a kind gift from J. Paton [59]. IgG binding to a panel of
bacterial proteins and multiple capsular serotypes were assessed using Luminex assays [55]
and electrochemiluminescence-based multiplex assay based on MesoScale Discovery (MSD,
Rockville, MD, USA) technology as previously described [13, 55, 60]. For immunoblotting,
bacterial lysates were separated by SDS-PAGE and transferred on to nitrocellulose membranes
as previously described [36]. Membranes were probed with IVIG (Intratect) or pooled human
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sera (1:1000). To assess IgG binding to the bacterial surface, flow cytometry was performed as
previously described [57, 61, 62].
In vitro functional assays
Effects of IVIG on bacterial aggregation during growth were assessed by inoculating THY with
1x106 of S. pneumoniae and measuing the OD580 over an 8 h period in the presence of 10%
IVIG (Intratect, 40mg/ml IgG) or PBS. Following 8 h growth, cultures were fixed onto polyly-
sine slides (VWR), stained with rapid Romanowsky staining (Diff-Quick) and imaged under
light microscopy (Olympus, BX40) at 100X using Q capture pro software. Bacterial aggrega-
tion was directly assessed by incubating bacteria diluted in PBS to 1X106 CFU/ml at 37˚C in
5%CO2 for 1 hr with 0%, 1%, 5%, 10%, IVIG (Intratect 40mg/ml IgG). After fixation in 50μl
10% NBF, particle size was asessed by flow cytometry using a FACSCalibur with Cellquest and
Flowjo software (BD Bioscience, UK) as a change in forward-scatter (FSC). Bacterial phagocy-
tosis was measured as previously described as the association of FAM-SE labelled bacteria with
either RAW 264.7 macrophages (MOI 10) [38, 53] or freshly isolated human neutrophils [57].
Briefly, RAW 264.7 murine cells were grown in RPMI supplemented with 10% heat-inacti-
vated foetal calf serum. After washing, they were infected with FAM-SE labelled bacteria at an
MOI of 10 which had been pre-incubated with IVIG or PBS for 30 mins at 37 C. After 45 min,
cells were harvested with trypsin, fixed with paraformaldehyde (PFA) and fluorescence
assessed using a FACS Calibur flow cytometer with Cellquest and Flowjo software (BD Biosci-
ence, UK). For neutrophil phagocytosis, similarly opsonised labelled bacteria were incubated
with freshly isolated human granulocytes for 30 min at MOI 20, after which they were fixed
with PFA and assessed by flow cytometry. To assess bacterial killing by human neutrophils,
pre-opsonised bacteria were incubated with freshly isolated granulocytes for 45 min after
which they were serially diluted, plated and incubated overnight prior to colony counting.
Murine infection models and assays
For passive immunisation experiments with IVIG, 6 to 8 week old age-matched outbred CD1
mice (Charles River, UK) received two i.p. injections of IVIG totalling 12.8mg IgG or the
equivalent volume of PBS 3 h prior and immediately before S. pneumoniae TIGR4. Challenges
were given either i.n. with 50μl of PBS containing 1x107 CFU or i.v. with 100μl of PBS contain-
ing 5x105 CFU. To ensure aspiration of the IN inoculum, mice were anaesthetised using 4%
halothane (Vet-Tech). At the designated time points after inoculation, mice were culled and
BALF, lung homogenates, and blood obtained for plating to calculate bacterial CFU as
described previously [19, 48]. BALF was collected by instilling the lungs with 1ml PBS via an
incision in the trachea. This was recovered by aspiration repeated three times. Splenic macro-
phages were depleted by i.v. administration of 100ul of 5mg/ml liposomal clodronate (controls
were given PBS liposomes) [38, 63]. Macrophage depletion was confirmed by a 50% reduction
in F4/80+ splenocytes by flow cytometry using anti-F4/80-phycoerythrin (Caltag). To deplete
Ly6G+ neutrophils, 600 μg anti-Ly6G monoclonal antibody (1A8m, Bioxcell) was adminis-
tered by i.p. injection 24 hours prior to infection challenge depletion, as previously [24], result-
ing in a 94.8% decrease in neutrophils recruited to lavage fluid 24 hours after infection.
Murine albumin was measured by ELISA using a commercially available kit following manu-
facturer’s instructions (Bethyl Laboratories). Murine TNF-alpha was measured by ELISA and
BALF cell counts in cytospins as previously described [24]. Human IgG was measured in
murine samples using a commercially available ELISA kit following manufacturer’s instruc-
tions (Cambridge Bioscience).
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Statistics
Data are presented as group means with error bars representing standard deviations (SDs).
Student’s unpaired T-test was used to compare the mean of two groups or analysis of variance
(ANOVA) for comparisons between multiple groups, using Bonferroni post-test comparisons.
F tests were used to assess if the slope of linear regressions were statistically different to 0. Sta-
tistical tests were performed using Graph Pad Prism software, and P values< 0.05 were con-
sidered significant.
Study approval
Experiments were approved by the UCL Biological Services Ethical Committee and the UK
Home Office (Project Licence PPL70/6510). Experiments were performed according to UK
national guidelines for animal use and care, under UK Home Office licence. Blood samples
were taken from human volunteers in Malawi with approval of the University of Malawi Col-
lege of Medicine Research and Ethics Committee and the Liverpool School of Tropical Medi-
cine Research Ethics Committee (Ref: 00.54).
Supporting Information
S1 Fig. Correlation between IgG binding in serum of individuals to total bacterial antigens
(whole cell ELISA titres) with binding to either the homologous capsular polysaccharide
(capsular ELISA titres, A-D) or with bacterial surface proteins (mean MFI for all protein
antigens in the Luminex assay, E-H). R-squared values were obtained using F-tests.
(PPTX)
S2 Fig. Cell counts in broncho-alveolar fluid 24 hours after challenge with 107 CFU S.
pneumoniae TIGR4 in IVIG-treated and PBS-control mice.
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